Compare Citius Pharmaceuticals Inc (CTXR) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs TORM plc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while TORM plc trades at $39.94 (market cap $4.12B). The key difference: TORM plc is far larger — about 302.5× Citius Pharmaceuticals Inc's market cap, and TORM plc pays a 11.03% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and TORM plc for 23 Days on average.
| CTXR | TRMD | |
|---|---|---|
Market Cap | $13.62M | $4.12B |
Volume | 132,438 | 2,863,116 |
Sector | Health | Industrials |
52-Week High | $1.82 | $41.05 |
52-Week Low | $0.48 | $19.39 |
Typical Hold Time | 17 Days | 23 Days |
Enterprise Value | $3.79M | $4.83B |
Dividend Yield | — | 11.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
TRMD trades at $40.06, up 2.93% today, with strong technical momentum showing bullish moving averages. The company demonstrates robust fundamentals with a P/E of 6.59, net income margin of 35.52%, and ROE of 26.84%. Recent earnings showed mixed results with Q2 2026 missing expectations, but 2026 projections indicate significant revenue growth to $1.8B. Analyst consensus is unanimously bullish with 100% buy ratings.
The outlook remains positive given strong profitability metrics and institutional interest, though risks include spot rate volatility in the tanker market and recent insider selling. Current valuation appears attractive relative to earnings power, but investors should monitor Q3 2026 earnings results against the $1.54 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
